Hikal Q3 FY26: Rs 92M loss post exceptional, revenue recognition review ongoing

Qualified audit opinionExceptional itemNet loss reportedRevenue declinedEmphasis of matterResults View source PDF Explain this filing

HIKAL · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+10.8%Reaction day

₹190.00

prior close

₹197.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.5%+11.3% vs market

Pharmaceuticals peers, median of 157sector-0.7%+11.4% vs sector

On the reaction day the stock moved 11.3 pts more than Nifty Microcap 250 and 11.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+5.4

10m

+7.0

15m

+7.2

30m

+8.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+10.8-0.5+11.3-0.7+11.4

Next day

+12.9-2.0+14.9-1.4+14.4

+10.1-2.7+12.7-2.1+12.2

+7.6-1.7+9.3-1.6+9.2

+8.4-1.4+9.9-1.6+10.0

+6.3-2.8+9.1-2.5+8.8

+7.6-2.8+10.4-2.9+10.5

15d

-4.7-8.4+3.7-6.5+1.8

-4.9-9.1+4.2-6.6+1.7

-4.2-4.0-0.2-3.3-0.9

+5.2+2.6+2.5+0.7+4.4

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Hikal reported Q3 FY26 standalone revenue of Rs 4,943M (up 10% YoY) but swung to a Rs 59M loss after a Rs 380M exceptional charge from new Labour Codes. 9M FY26 revenue fell 9% to Rs 11,932M with a Rs 633M loss versus Rs 406M profit a year ago. Pharma sales were hurt by a USFDA warning letter at the Jigani facility. Auditors gave a modified review due to an ongoing probe into revenue recognition irregularities. Interim dividend of Rs 0.20 per share declared.

Likely market impact

Modified audit opinion, USFDA action, and revenue recognition probe raise governance and earnings concerns despite dividend declaration.